QOL Medical’s Sucraid Is First To Lose Its REMS

In the brief history of Risk Evaluation and Mitigation Strategies, QOL Medical’s enzyme replacement therapy Sucraid stands out for the unusual reason behind the REMS requirements in the first place, and because it was the first and only product to date to be released from its risk management obligations.